Repatha (Evolocumab): History and Development

The Discovery of PCSK9: A Genetic Accident That Reshaped Lipidology

The story of evolocumab begins not in a pharmaceutical lab but in a genomics facility in Montreal. In 2003, Nabil Seidah and colleagues at the Institut de Recherches Cliniques de Montréal identified a novel serine protease they named proprotein convertase subtilisin/kexin type 9, or PCSK9 [1]. The protein had no known clinical role at the time.

That changed within months. A French research group led by Marianne Abifadel reported that gain-of-function mutations in the PCSK9 gene co-segregated with autosomal dominant hypercholesterolemia in two families, establishing the first direct link between PCSK9 and elevated LDL cholesterol [2]. Patients carrying these mutations had severely high LDL-C levels despite no mutations in the LDL receptor or apolipoprotein B genes.

The clinical picture sharpened in 2006. Jonathan Cohen and Helen Hobbs at UT Southwestern analyzed the Dallas Heart Study cohort and found that individuals with loss-of-function PCSK9 mutations had 28% lower mean LDL-C and an 88% reduction in coronary heart disease risk over a 15-year follow-up [3]. That 88% figure caught the attention of every major cardiovascular drug developer. The implication was direct: blocking PCSK9 could lower LDL and reduce heart disease. A race began.

From Target to Molecule: How Amgen Built Evolocumab

Amgen entered PCSK9 drug development in 2007, selecting a fully human monoclonal antibody approach. The company used its XenoMouse technology platform, which generates human IgG antibodies in transgenic mice, to produce a candidate molecule initially designated AMG 145. This molecule would later be named evolocumab.

Why a monoclonal antibody and not a small molecule? PCSK9 is a secreted protein that acts on the surface of hepatocytes. Antibodies offered high target specificity and a clean binding profile. They could be engineered to grab PCSK9 in the bloodstream before it reached the LDL receptor. Amgen was not alone in this approach. Regeneron and Sanofi were developing alirocumab (later branded Praluent) along a parallel track, and Pfizer had its own candidate, bococizumab.

The first human data emerged in 2012. A phase 1 study published in the Journal of the American College of Cardiology showed that a single subcutaneous dose of AMG 145 reduced LDL-C by up to 64% in statin-treated patients [4] with hypercholesterolemia. The reductions were dose-dependent and lasted two to four weeks. No serious safety signals appeared. Amgen moved quickly into phase 2 and then into the large-scale PROFICIO program.

How Evolocumab Works: Blocking PCSK9 at the Hepatocyte Surface

The mechanism is specific. LDL receptors on liver cells bind circulating LDL particles and pull them into the cell for degradation, lowering blood LDL-C levels. Under normal physiology, the liver recycles these receptors back to the cell surface roughly 150 times before they wear out. PCSK9 interferes with that recycling.

When PCSK9 binds to an LDL receptor on the hepatocyte surface, it tags the receptor for lysosomal destruction instead of recycling. Fewer receptors return to the surface. Fewer LDL particles get cleared. LDL-C rises.

Evolocumab binds circulating PCSK9 with high affinity, preventing the protein from ever reaching the LDL receptor. The result: more LDL receptors survive on the hepatocyte surface, and more LDL particles get pulled from the bloodstream. The mechanism is additive to statins [5], which lower LDL-C partly by upregulating LDL receptor expression but also increase PCSK9 levels as a compensatory response. Blocking PCSK9 on top of a statin removes that compensatory brake.

This explains why the combination of a statin plus evolocumab can reduce LDL-C by 60% or more from baseline. Dr. Robert Giugliano, a cardiologist at Brigham and Women's Hospital and co-investigator of the FOURIER trial, described the interaction: "Statins increase both LDL receptors and PCSK9. By neutralizing the PCSK9 that statins induce, evolocumab allows the full benefit of upregulated LDL receptors to take effect" [5].

The PROFICIO Clinical Program: Twelve Trials, One Goal

Amgen's clinical development program for evolocumab, called PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations), enrolled over 35,000 patients across more than a dozen phase 2 and phase 3 trials. The program covered heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), statin-intolerant patients, and patients with established atherosclerotic cardiovascular disease (ASCVD).

Key efficacy trials within PROFICIO included:

MENDEL-2 (N=614): Evolocumab as monotherapy in patients with hypercholesterolemia not on statins. LDL-C dropped 55% to 57% [6] versus placebo at 12 weeks.

LAPLACE-2 (N=1,896): Evolocumab added to moderate- or high-intensity statin therapy. LDL-C reductions ranged from 63% to 75% [7] versus placebo depending on the statin backbone.

RUTHERFORD-2 (N=329): Evolocumab in patients with HeFH already on statins. LDL-C fell 59% to 61% [8] below placebo at 12 weeks.

TESLA Part B (N=49): Evolocumab in HoFH, a rare and severe genetic condition. Even in patients with two defective LDL receptor alleles, evolocumab reduced LDL-C by approximately 31% [9]. This was a meaningful result for a population with very few treatment options.

GAUSS-2 (N=307): Evolocumab in statin-intolerant patients. LDL-C fell 53% to 56% [10] compared to ezetimibe.

The OSLER open-label extension studies then followed these patients longer term. OSLER-1 and OSLER-2 combined (N=4,465) showed sustained LDL-C reductions of 61% over 11 months and a post hoc analysis suggested a 53% lower rate of cardiovascular events, though the studies were not powered for outcomes [5].

The FOURIER Trial: First Proof That PCSK9 Inhibition Prevents Cardiovascular Events

FOURIER was the trial the cardiology world waited for. Reducing LDL-C is only valuable if it translates into fewer heart attacks, strokes, and cardiovascular deaths. The statin trials had proven this relationship. PCSK9 inhibitors needed to prove it again at much lower LDL levels.

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) randomized 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or higher (despite statin therapy) to evolocumab or placebo. The median follow-up was 2.2 years. The trial was led by Marc Sabatine at the TIMI Study Group, Brigham and Women's Hospital, and published in the New England Journal of Medicine in March 2017 [11].

The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% in the placebo group. That is a 15% relative risk reduction (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). The key secondary endpoint of cardiovascular death, MI, or stroke fell 20% (HR 0.80, 95% CI 0.73 to 0.88, P<0.001) [11].

Evolocumab reduced LDL-C from a median of 92 mg/dL to 30 mg/dL, a 59% drop. Safety data showed no increase in neurocognitive events, new-onset diabetes, or myalgia versus placebo. An important observation: the benefit appeared to grow over time. In the first year, the reduction in MI and stroke was modest. By year two and beyond, the curves separated more sharply.

Dr. Marc Sabatine stated in a presentation following publication: "For the first time, we demonstrated that inhibiting PCSK9 on top of statin therapy significantly reduces cardiovascular events in patients with established disease. The FOURIER results also reaffirmed that lowering LDL to levels well below current targets is safe and incrementally beneficial" [11].

The GLAGOV Trial: Seeing Plaque Regress on Imaging

Before FOURIER reported, the GLAGOV trial provided an anatomical proof of concept. This intravascular ultrasound (IVUS) study randomized 968 patients with angiographic coronary disease to evolocumab or placebo on top of statin therapy. After 76 weeks, patients on evolocumab had a statistically significant decrease in percent atheroma volume (PAV) of 0.95 percentage points versus an increase of 0.05 points with placebo (P<0.001). A total of 64.3% of evolocumab patients showed plaque regression compared to 47.3% on placebo [12].

These imaging results aligned with earlier statin trials showing that aggressive LDL lowering shrinks coronary plaques. GLAGOV confirmed the same biology applied at the extremely low LDL-C levels achieved by PCSK9 inhibition.

FDA Approval Timeline and Label Expansions

The regulatory history of evolocumab proceeded in stages.

August 27, 2015: The FDA approved Repatha for adults with HeFH or clinical ASCVD who require additional LDL lowering, and for patients with HoFH [13]. The approval was based on LDL-C lowering data from the PROFICIO program. At this point, no cardiovascular outcomes data existed for any PCSK9 inhibitor.

December 2017: Following FOURIER, the FDA approved a supplemental indication for evolocumab to reduce the risk of MI, stroke, and coronary revascularization in adults with established ASCVD [13]. This was a significant label expansion. Evolocumab shifted from a lipid-lowering agent with a surrogate-endpoint approval to a drug with proven cardiovascular outcomes benefit.

2020: The FDA approved a new 420 mg single-dose prefilled cartridge for use with the SureClick autoinjector, reducing the injection burden for patients on monthly dosing from three separate 140 mg injections to one [13].

The European Medicines Agency (EMA) granted marketing authorization in July 2015, slightly before the FDA approval, covering similar indications [14].

Pricing, Access, and the Broader PCSK9 Market

Evolocumab launched at a US list price of approximately $14,100 per year. The Institute for Clinical and Economic Review (ICER) assessed PCSK9 inhibitors in 2015 and concluded that the clinical benefit was clear but the price would need to fall to roughly $2,200 to $5,000 annually to meet conventional cost-effectiveness thresholds at the time. Insurers responded by erecting substantial prior authorization barriers.

Amgen reduced the list price of Repatha by 60% in 2018, bringing it to roughly $5,850 per year [15]. This was one of the largest voluntary price cuts for a branded biologic in the US market. Amgen CEO Robert Bradway stated that the company lowered the price "to reflect evolocumab's proven cardiovascular benefit and to improve patient access."

The 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol positioned PCSK9 inhibitors as reasonable add-on therapy for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. The guideline stated: "In very high-risk patients, a PCSK9 inhibitor is reasonable if LDL-C remains ≥70 mg/dL on maximally tolerated LDL-lowering therapy" (2018 AHA/ACC Guideline) [16]. That recommendation helped standardize insurance coverage criteria.

Where Evolocumab Stands in 2026

Two decades after the discovery of PCSK9, evolocumab has accumulated over 10 years of real-world post-marketing exposure. Long-term open-label extension data from the FOURIER-OLE study showed that patients treated with evolocumab for a median of 5 years maintained consistent LDL-C lowering with no new safety signals, and the cardiovascular benefit continued to accrue over extended follow-up [17].

The competitive field has also shifted. Inclisiran (Leqvio), an siRNA that silences PCSK9 production at the mRNA level, received FDA approval in 2021 and offers twice-yearly dosing administered by a healthcare professional. Bempedoic acid (Nexletol) provides an oral non-statin option for patients who cannot tolerate statins. Yet evolocumab retains advantages: strong cardiovascular outcomes data from FOURIER, flexible self-injection at home, and a decade of safety follow-up that newer agents have not matched.

For clinicians managing patients with ASCVD and persistently elevated LDL-C despite maximally tolerated statin and ezetimibe, the 2018 AHA/ACC guideline pathway remains the standard decision point for adding evolocumab. Checking a fasting lipid panel 4 to 6 weeks after initiating therapy confirms response, with an expected LDL-C reduction of 55% to 65% from the pre-treatment value [16].